Kannari 2 Study Protocol

The Kannari 2 study, conducted by Santé publique France, aims to assess the levels of chlordecone and other environmental pollutants in the population of the French West Indies (Guadeloupe and Martinique), ten years after the completion of the Kannari 1 study (2013–2014). This cross-sectional biomonitoring study focuses on adults (aged 18 and older) as well as children (aged 6 to 17), with particular attention paid to vulnerable subgroups, such as women of childbearing age, agricultural workers, and fishermen. Its main objectives are to monitor trends in body burden levels of chlordecone and other pollutants such as pesticides and heavy metals, to identify associated risk factors—whether related to diet, occupational or environmental exposure, and to study the influence of social inequalities as well as knowledge, attitudes, and practices (KAP) on this exposure. Finally, it aims to estimate the proportion of the population whose plasma chlordecone levels exceed the toxicological reference value (TRV) set at 0.4 µg/L. Regarding methodology, sampling is based on a random draw from the databases of the General Social Security Funds (CGSS), with stratification based on whether the areas are contaminated or not. Data collection is conducted using questionnaires administered during three home visits, covering dietary habits, occupational and household exposures, as well as chemical exposure pathways (CAPs). Biological samples (blood for the measurement of chlordecone, lead, and other metals, and urine for pesticides and their metabolites) are also collected, along with anthropometric measurements and blood pressure readings. The analyses are performed by specialized laboratories, and the samples are stored in a biobank. The benefits of the Kannari 2 study are both collective and individual. On a collective level, it contributes to the Chlordecone Plan IV (2021–2027) and helps tailor public health recommendations. For participants, it provides feedback in the form of laboratory results and a dietary recommendations booklet, with enhanced support for individuals with chlordecone levels of 0.4 µg/L or higher. The pilot phase took place between June and July 2023, involving 101 adults and 50 children per region, followed by the main study from January to July 2024. The results will be published starting in September 2026. From an ethical standpoint, informed consent is required for adults and the legal guardians of minors. Data protection is ensured through pseudonymization, encryption, and compliance with the GDPR. Approval has been obtained from the Committee for the Protection of Human Subjects (CPP) and the CNIL. Finally, the results will be disseminated through reports, scientific articles, and public outreach via the website www.kannari2.fr.

Author(s): Saoudi Abdessattar, Teissier Anne, Assogba Frank, Jehanin Pascal, Delamaire Corinne, Dereumeaux Clémentine, Pécheux Marie, Richard Jean-Baptiste, Cornély Vanessa, Rosine Jacques, Martias Cécile, Ruello Marc

Publishing year: 2026

Pages: 145 p.

Collection: Method

In relation to

Our latest news

Appel à candidatures d'experts pour le remplacement d’un membre « sage-femme » du Comité national d'experts sur la mortalité maternelle (CNEMM)

news

Call for Nominations to Fill Vacancies on the National Reference Centers...

news

Public Health France Conference: November 9, 2026

news

Shamonda Virus: First Human Case Detected in France—What Do We Know?